(Q36770348)

16 August 2017

1 reference

title

Imatinib: a review of its use in the management of gastrointestinal stromal tumours (English)

1 reference

16 August 2017

1 reference

2

Lesley J Scott

1 reference

16 August 2017

M Asif A Siddiqui

1

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

67

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

805-820

1 reference

Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib

16 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767050-00012

Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767050-00012

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

12 December 2020

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

1 reference

12 December 2020

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

1 reference

12 December 2020

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

1 reference

12 December 2020

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

1 reference

12 December 2020

Interaction of imatinib mesilate with human P-glycoprotein

1 reference

12 December 2020

Imatinib: a review of its use in chronic myeloid leukaemia

1 reference

12 December 2020

Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

12 December 2020

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Biology of gastrointestinal stromal tumors.

1 reference

12 December 2020

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

12 December 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

12 December 2020

Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors

1 reference

12 December 2020

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

12 December 2020

Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.

1 reference

12 December 2020

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

1 reference

12 December 2020

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

12 December 2020

Gastrointestinal stromal tumor: 5 years later

1 reference

12 December 2020

Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography

1 reference

12 December 2020

Effect of St John's wort on imatinib mesylate pharmacokinetics

1 reference

12 December 2020

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

12 December 2020

Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion

1 reference

12 December 2020

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

12 December 2020

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects

1 reference

12 December 2020

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

1 reference

12 December 2020

Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study.

1 reference

12 December 2020

The anticancer drug imatinib induces cellular autophagy.

1 reference

12 December 2020

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours

1 reference

12 December 2020

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

1 reference

12 December 2020

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

1 reference

12 December 2020

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

1 reference

12 December 2020

Metabolism and disposition of imatinib mesylate in healthy volunteers

1 reference

12 December 2020

KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications

1 reference

12 December 2020

Clinical pharmacokinetics of imatinib

1 reference

12 December 2020

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

1 reference

12 December 2020

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

1 reference

12 December 2020

1 reference

12 December 2020

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00003495-200767050-00012

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1050063461

0 references

1 reference